Scientific Presentations

2018

Insights into Cancer Immunosurveillance and a Vision for Improving Patient Outcomes with Combination Immunotherapy
Grand Rounds, Oncology Center of Excellence, US FDA, White Oak, MD, April 27, 2018

Future Directions: Combination Therapy and Moving to Early Stage Setting.
Immunotherapy Conference, Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 13, 2018

Developing NextGen Combination Immunotherapies that will Tackle the Worst Cancers.
Seminar, Division of Medical Oncology, SingHealth Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 11, 2018

Combo immunotherapies hold great promise for better outcomes and more cures.
Answer2Cancer, Portland Oregon, April 7, 2018

Sequencing Checkpoint Therapies
Keystone Symposia, “Cancer Immunotherapy: Combinations” Montreal, Quebec, Canada March 23-27, 2018

Investigating Crucial Factors that Determine the Success of Immune Checkpoint Combinations
Immune Checkpoint Inhibition Meeting, Boston, MA, March 20-21, 2018

Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies
Perlmutter Cancer Center, New York University, NY, NY, March 14, 2018

Immunoscore: A Brief History, Clinical Application and Strategies to Move IHC-Based Evaluations of Cancer to Stratify patients for Clinical Trials and Tailor Therapy.
Thoracic Oncology Centre Munich (TOM): “State of the Art 2018“ meeting, Munich, Germany, March 8 – 10, 2018

A Vision to Exploit NCI Prioritized Cancer Antigens and TCGA Data to Develop Combination Immunotherapy for Rare Cancers.  
Keynote Address, International Workshop on Merkel Cell Carcinoma Research, Center for Cancer Research (CCR) Rare Tumor Initiative, National Cancer Institute (NCI) Shady Grove Campus, Rockville, Maryland, March 5, 2018

Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies that will Tackle the Worst Cancers.
University of Michigan Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, February 7, 2018

Development of Cancer Vaccine-Based Combination Immunotherapy Strategies to Conquer Cancer.
Invited Presentation, Noble Life Science Partners Scientific Advisory Board, Ft. Lauderdale, FL, January 29, 2018


2017

Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy with T cell Agonists
Immunotherapy Bridge Meeting, Napoli, Italy, November 29, 2017

Update on immuno-oncology
IASLC and Taiwan Lung Cancer Society meeting, Taipei, Taiwan, October 28, 2017

Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans
Powering Precision Medicine. Boston, MA Oct 24, 2017

Agonistic antibodies in the era of antagonistic antibodies: monotherapy, combination and/or sequence
Sienna Consensus Conference, NIBIT and the Parker Foundation, Siena, Italy, October 7, 2017

Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures
Radium Hospitalet, University of Oslo, Oslo, Norway. Sept 1, 2017

Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy
Karolinska Institute, IMTAC Immunology Summer Course, Sandhamn Island, Sweden August 28-30, 2017

How I-O Agents and Combination Therapies Change the Biomarkers: Information to Tailor Therapy  
Next-Generation-Dx-Summit, Washington DC, August 18, 2017

Three Important Considerations for Developing Effective Imuno-Oncology Combinations: Immunity, Co-stimulation and Checkpoint Blockade
FDA-AACR: Oncology Dose Finding Workshop Part 3, Washington DC, July 20, 2017 https://www.fda.gov/Drugs/NewsEvents/ucm562746.htm

Progress in Immuno-oncology: Delivering Hope and Clinical Benefit to Cancer Patients
AACR-SITC Joint Congressional Briefing
Russell Senate Office Building, Capitol Hill, Washington DC, July 19, 2017 http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/AACR-SITC-congressional-briefing.aspx?source=social&medium=Facebook&campaign=public%20affairs#.WX5nQq2ZPeQ

NextGen Biomarkers for Precision Immunotherapy and a strategy to Impersonalize Cancer
Institute for Systems Biology (ISB) Summer Course, Seatle, WA, June 21-22, 2017

Hurdles to Developing Combination Immunotherapy: Insights from Preclinical Studies of Agonists Plus Checkpoint Blockade and a NextGen Approach to Characterizing Immune Cells in Human Tumors
Celldex Scientific Advisory Board Meeting, ASCO, Chicago, IL, June 5, 2017

Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans: Holbrook Kohrt, MD, PhD, Memorial Lecture
ICVI Symposium, Royal Society, London, UK, May 13, 2017

Evaluation of the Anti-Cancer Immune Response in Tumors
Definiens Syposium, Amsterdam, The Netherlands, April 25-26, 2017

The Elements to Cure Cancer by Immunotherapy
Taiwan Society for Immunotherapy of Cancer, Taiwan, April 22, 2017

Possible Solutions to the Biggest Hurdles for Immuno-Oncology.
Venture Forum, World Vaccine Conference, Washington DC, April 12, 2017

Immuno-Oncology at a Tipping Point.
17th Annual World Vaccine Conference, Washington DC, April 12, 2017

Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures, Immuno-Oncology Combination Therapies:
FDA Policy Forum, Regulatory Science and Policy Tracks at the AACR Annual Meetings http://www.abstractsonline.com/pp8/#!/4292/session/127 Washington DC, April 4, 2017

Possible Solutions to the Biggest Hurdles for Immuno-Oncology
Sachs Venture Forum, New York, NY,  March 28, 2017

Multispectral Imaging of the Tumor Environment: Focus on HPV- HNSCC

ITOC 4, Prague, CZ, March 19, 2017

Antigen Presentation Defects and Cytokine Storm - Mechanisms Cancer Exploits to Escape
International Immuno-Oncology Network, London, UK, February 28, 2017  


2016

Basic Biology of Immunotherapy: Cancer Vaccine, Immune Checkpoint Therapy and More
Chinese University of Hong Kong, Hong Kong, China, November 19, 2016

Immunoscore/Immunoprofiling and Combination Immunotherapy Including Vaccines
World Life Science Conference, Beijing, China, Nov. 2, 2016

A Perspective on the Future of Immuno-Oncology Research
3rd Immuno-Oncology Academy, Taipei, Taiwan, Oct 29, 2016

Immuno-Oncology at a Tipping Point
Loyola University: Cardinal Bernardin Cancer Center Retreat
Chicago, IL - July 29, 2016

Impersonalization of Cancer: Development of a Universal Cancer Vaccine
University of Washington: MITR Conference
Seattle, WA, July 18, 2016

Impersonalization of Cancer: Development of a Universal Cancer Vaccine
Agonox Maui Meeting
Maui, HI - June 10, 2016

UbiVac
Sachs Immuno-Oncology Investor Forum
Chicago, IL - June 3, 2016


Recent Advances for the Immunotherapy of Advanced Cancer
Taiwan Joint Cancer Conference: Molecular Genetics Section
Taipei, Taiwan - May 14, 2016

Immuno-Oncology at a Tipping Point
Bayer
Berlin, Germany - May 2, 2016

A Universal Cancer Vaccine Alternative to Personalized Cancer Vaccine Strategies
Tumor Immunology Meets Oncology (TIMO)
Halle, Germany - April 28, 2016

Increased IgG Antibody Responses to Neoepitope and Native Peptides Containing High Affinity Domains for MHCI
AACR, Poster presented by Tyler W. Hulett
New Orleans, LA - April 16-20, 2016

Timing Of PD-1 Blockade Is Critical To Successful Synergy With OX40 Costimulation In Preclinical Mammary Tumor Models
AACR, Oral presentation, David Messenheimer
New Orleans, LA - April 16-20, 2016

Immunotherapy at a Tipping Point
Molecular Med TriCon
San Francisco, CA - March 10-11, 2016

Cancer Vaccines and Combination Immunotherapy. At Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer
The National Academies of Sciences, Engineering, and Medicine: Institute of Medicine
Washington, DC 20001 - February 29, 2016

The Promise of Immunotherpy in Curing Patients with Cancer
Annual meeting of the Oncology Association of Naturopathic Physicians
Phoenix, AZ - February 28, 2016

The Next Phase for Cancer Immunotherapy
Janssen Research Center
Leiden, Netherlands - February 8, 2016

Clinical Updates for Novel Targets and Pathways: Application of Technologies and What They Tell Us?
PEP Talk
San Diego - January 18, 2016